STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #563 by analyst upside · 2026-08-13
SLN
Silence Therapeutics plc
Healthcare · Market Cap $641M · P/E 0x
ANALYST PRICE TARGET
+162.2%
implied upside to consensus target
Current Price $13.58
Consensus Target $35.6
Bull Target $75.0
Bear Target $19.0
Analysts Covering 5
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
4
Hold
0
Sell
0
52-Week Low $4.19
52-Week High $17.58
YTD Return +120.8%
FUNDAMENTALS
Market Cap $641M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-1.19
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $1M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $4.19
52-Week High $17.58
Current Price $13.58
Bear Target $19.0
Bull Target $75.0
● Now $13.58 ● Target $35.6
TRADING DATA
Avg Volume 749K
YTD Return +120.8%
Analyst Count 5
Consensus Buy
Upside to Target +162.2%
Last Updated 2026-08-13

ANALYST SUMMARY

Silence Therapeutics plc (SLN) is currently trading at $13.58 with a Wall Street consensus price target of $35.6, implying potential upside of 162.2% over the next 12 months. 5 analysts currently cover SLN, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $75.0, while the most cautious has a target of $19.0.

SLN operates in the Healthcare sector with a market capitalisation of $641M. The stock is up 120.8% year-to-date and is currently trading near the upper end of its 52-week range of $4.19 – $17.58.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for SLN, with each firm's 90-day track record across all stocks we track. See full firm rankings →

HC Wainwright & Co. reit
Buy → Buy 2026-06-17 31% win rate (48 calls)
HC Wainwright & Co. reit
Buy → Buy 2026-03-13 31% win rate (48 calls)
HC Wainwright & Co. reit
Buy → Buy 2025-09-16 31% win rate (48 calls)
Chardan Capital - Reiterated
Buy → Buy 2025-08-08 33% win rate (6 calls)
HC Wainwright & Co. reit
Buy → Buy 2025-06-13 31% win rate (48 calls)
Chardan Capital - Reiterated
Buy → Buy 2025-06-13 33% win rate (6 calls)
Goldman Sachs - Reiterated
Sell → Sell 2025-05-09 Building track record
Morgan Stanley - Reiterated
Overweight → Overweight 2025-05-09 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
41
out of 100
Coverage depth
14/30
Consensus clarity
0/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →